Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Suraksha Diagnostic Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹441
Per ShareLot Size
34 Shares
Minimum Investment
₹14,994
Issue Size
₹846.25 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
61.07%
Promoter Holding (Post-Issue)
48.78%
Issue Type
Book Building
ISIN
INE877V01027
We offer one stop integrated solutions for pathology and radiology testing and medical consultation services including X-rays, ultrasonography, computerized tomography, magnetic resonance imaging scans and vaccination services through our operational network, consisting of our flagship central reference laboratory, 8 satellite laboratories (co-located with our diagnostic centers) and 215 customer touchpoints which include 49 diagnostic centres, and 166 sample collection centres (primarily franchised), as of June 30, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya. We generate revenue primarily through sales of our diagnostic services as mentioned above.
The Indian diagnostics services market, estimated to at Rs.860 to Rs.870 billion in Fiscal 2024, is projected to grow at CAGR of around 10%-12% to Rs.1,275-Rs.1,375 billion by Fiscal 2028, out of which the eastern and north-eastern India market, estimated at Rs.170-Rs.180 billion in Fiscal 2024, is projected to grow at CAGR of around 10.50%-12.50% to Rs.260-Rs.280 billion by Fiscal 2028. (Source: CRISIL Report, as replicated on page 196). Particularly, the West Bengal market, estimated at Rs.61 to Rs.63 billion in Fiscal 2024, is projected to grow at CAGR of around 10.50%-12.50% to Rs.95 to Rs.100 billion by Fiscal 2028.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 19,189,330 equity shares of face value of Rs. 2 each of Suraksha Diagnostic Limited (the "Company" or the "Issuer") for cash at a price of Rs. 441 per equity share (including a premium of Rs. 439 per equity share) (the "Offer Price") aggregating to Rs. 846.25 crores through an offer for sale of 19,189,330 equity shares of face value of Rs. 2 each aggregating to Rs. 846.25 crores, comprising 2,132,148 equity shares of face value of Rs. 2 each aggregating to Rs. 94.03 crores by Somnath Chatterjee, 2,132,148 equity shares of face value of Rs. 2 each aggregating to Rs. 94.03 crores by Ritu Mittal, 2,132,148 equity shares of face value of Rs. 2 each aggregating to Rs. 94.03 crores by Satish Kumar Verma (whose shares are jointly held with Suman Verma) (together with Somnath Chatterjee and Ritu Mittal, the "Promoter Selling Shareholders"), 10,660,737 equity shares of face value of Rs. 2 each aggregating to Rs. 470.14 crores by Orbimed Asia ii Mauritius Limited^ (the "Investor Selling Shareholder"), 799,556 equity shares of face value of Rs. 2 each aggregating to Rs. 35.26 cores by Munna Lal Kejriwal, and 1,332,593 equity shares of face value of Rs. 2 each aggregating to Rs. 58.77 crores by Santosh Kumar Kejriwal (together the "Individual Selling Shareholders") (the promoter selling shareholders, the investor selling shareholder and the individual selling shareholders, collectively referred to as the "Selling Shareholders", and such equity shares offered by the selling shareholders, the "Offered Shares") (the "Offer" or the "Offer for Sale"). The offer constitutes 36.84% of the post-offer paid-up equity share capital of the company. ^ Surviving entity pursuant to amalgamation of orbimed Asia ii Mauritius fdi investments limited, the erstwhile shareholder, into orbimed asia ii mauritius limited on november 11, 2022 The face value of the equity shares is Rs. 2 each and the offer price is 220.5 times the face value of the equity shares.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Our Company was incorporated as `Suraksha Diagnostic Private Limited' as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata. Subsequently, our Company was converted into a public limited company pursuant to a special resolution passed in the extra-ordinary general meeting of our Shareholders held on June 5, 2024, and consequently, the name of our Company was changed to `Suraksha Diagnostic Limited', and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.